|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18.
|
31492932 |
2020 |
|
Adenoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytokeratin 7 and especially cytokeratin 17 highlighted the presence of ducts in the hyperplastic lesion, which are not present in adenomas. p16 and p53 were negative and Ki-67 immunostaining demonstrated similar low proliferation indices for normal and hyperplastic glands.
|
31593035 |
2020 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18.
|
31492932 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, patients with NSCLC with negative P16 expression demonstrated poor disease-free and disease-specific survival in multivariate analysis.
|
31662516 |
2020 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All IPs and associated SCCs were negative for p16 and hrHPV. lrHPV RNA was detected in 5/42 (12%) cases, including 3/5 (60%) with associated SCC (P=0.009).
|
31743131 |
2020 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18.
|
31492932 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When compared to a reference of tumor tissue p16 IHC in 783 OPSCC patients, the clinic-HPV<sub>sero</sub> model incorporating a composite of 20 HPV serological antibodies (HPV<sub>sero</sub> ) and 4 clinical factors (c-index: 0.96) performed better than using HPV<sub>sero</sub> (c-index: 0.92) or HPV<sub>mi</sub> (c-index: 0.76) alone.
|
31269236 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor histology correlated well with p16 positivity (P<.001) and p16 IHC accurately predicted the presence of HPV in 25/26 (96%) cases.
|
31698006 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DNA mismatch repair protein expression studies disclosed loss of nuclear immunostaining of MSH6 protein, pointing to the possibility of an underlying rare MSH6 variant of the Muir-Torre syndrome, not yet described in the ophthalmic literature. p16 nuclear positivity was also found in the tumor cells, indicating the possible role of high-risk human papillomavirus as an additional factor in the genesis of the tumor.
|
31557488 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Seven tissue microarrays were constructed. p16 protein expression was studied in 114 cases, of which 35/114 (30.7%) cases showed strong expression and the majority of them had ER-positive tumor (57.6%), and it was statistically significant (P < 0.0074).
|
31603125 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18.
|
31492932 |
2020 |
|
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There have been many attempts to predict the prognosis of lung cancer based on the expression patterns of P16 protein, but with limited success.
|
31662516 |
2020 |
|
Malignant Head and Neck Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Eighth AJCC head and neck cancer staging criteria were used to evaluate positive P16 expression (moderate/strong nuclear expression intensity and distribution >75% cells) in NSCLC.
|
31662516 |
2020 |
|
Squamous cell carcinoma of vulva
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty-eight patients with vulvar squamous cell carcinoma treated with primary radiation therapy were identified: 26 p16 positive/HPV-associated patients and 22 p16 negative/HPV-independent patients. p16 positive vulvar squamous cell carcinoma demonstrated a significantly improved overall survival (HR 0.39, p=0.03) and progression-free survival (HR 0.35, p=0.02).
|
31771962 |
2020 |
|
Cervix carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there is little information on the possible impact of the HPV genotype and p16 immunostaining on the clinicopathological features or their prognostic value in cervical carcinoma.
|
31492932 |
2020 |
|
Human papilloma virus infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular tests (in situ hybridization and polymerase chain reaction) showed no evidence of human papillomavirus infection and p16 staining was negative.
|
30480645 |
2020 |
|
Human papilloma virus infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study demonstrated that the p16 positive immunostaining was seen in the majority of primary vulvar EMPD which is not related to HPV infection.
|
31033795 |
2020 |
|
Human papilloma virus infection
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HPV infection (n=9, 8.9%) and p16 overexpression (n=15, 14.9%) were associated with better overall survival (P=0.0042 and 0.005, respectively).
|
31743130 |
2020 |
|
Human papilloma virus infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to assess utility of such histological features and p16 as surrogate markers of HPV infection in a retrospective cohort of 33 cases of severe epithelial dysplasia, with matched clinicopathological data and histological features.
|
31617604 |
2020 |
|
Human papilloma virus infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry for p16 (as a surrogate for high-risk HPV infection) and p53 was performed.
|
31771962 |
2020 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There have been many attempts to predict the prognosis of lung cancer based on the expression patterns of P16 protein, but with limited success.
|
31662516 |
2020 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Negative P16 expression was significantly associated with NSCLC with lymph node metastasis (p=0.025).
|
31662516 |
2020 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the multivariate analysis, negative p16 immunostaining was associated with a worse overall survival together with advanced FIGO stage and lymph node metastases.
|
31492932 |
2020 |
|
Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to assess utility of such histological features and p16 as surrogate markers of HPV infection in a retrospective cohort of 33 cases of severe epithelial dysplasia, with matched clinicopathological data and histological features.
|
31617604 |
2020 |
|
Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, knowing the overlapping p16 immunostaining patterns in vulvar EMPD and usual type vulvar intraepithelial neoplasm is important to render the correct diagnosis.
|
31033795 |
2020 |